Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

Harbour Biomed Announces Ind Approval For Phase Ii Trial Of Anti Fcrn Batoclimab In Chronic Inflammatory Demyelinating Polyneuropathy In China

Facebook Comments

Leave a Reply

CommentLuv badge